Vorige

Prof.dr. M. (Miriam) Koopman

Internist- oncoloog

Aandachtsgebieden

Aandachtsgebieden


Afdelingen / poliklinieken

Afdeling en poliklniniek

Divisie


Prof. Miriam Koopman in MLDS-video

Keuzehulp bij darmkanker

Lidmaatschap beroepsorganisaties

 

(werkgerelateerde) nevenfuncties


Prijzen, onderscheidingen

Februari 2017              

Uitgeroepen tot  promotor van het jaar 2017 in de Graduate School of Life Sciences Utrecht

December 2011    

Geselecteerd voor het het Steyn Parvé Programma (programma voor getalenteerde vrouwelijke onderzoekers, UMC Utrecht).

8 oktober 2010            

Best Poster Award: “Incidence and prognostic value of BRAF mutation in metastatic colorectal cancer (CRC) with mismatch repair deficiency (dMMR)”, ESMO Congres, Milaan, Italië.

13 november 2009            

Proefschrift, cum laude: “Towards an optimal use of chemotherapy in advanced colorectal cancer patients”.

25 april 2008            

Best Clinical Research Paper 2007: Annual Meeting of the Nederlandse Internisten Vereniging (NIV), Maastricht: “Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer, a Dutch Colorectal Cancer Group (DCCG) phase III study. Lancet 2007;370:135-42.

6 december 2007            

Dr. I.B.M. Frye Stipendium - Individuele onderzoekssubsidie voor jonge excellente vrouwelijke onderzoekers, om een internationaal onderzoeksproject te kunnen uitvoeren, Radboud Universiteit Nijmegen

Juni 2007              

Geselecteerd als deelnemer aan de FECS-AACR-ASCO Workshop 'Methods in clinical cancer research', Flims, Zwitserland.

Juni 2006              

Toekenning van de jaarlijkse onderscheiding voor de beste arts-assistent Interne Geneeskunde. Radboud Universiteit Nijmegen.

30 juni 2000            

Promotie cum laude.

Wetenschappelijk onderzoek

Publicaties

Key Publications

  • Simkens LHJ, van Tinteren H, May A,  ten Tije AJ, Creemers GJM, Loosveld OJL, de Jongh FE, Erdkamp FLG, Erjavec Z, van der Torren AME, Tol J, Braun HJJ, Nieboer P, van der Hoeven JJM, Haasjes JG, Jansen RLH, Wals J, Cats A, Derleyn VA, Honkoop AH, Mol L, Punt CJA, Koopman M. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer, the phase 3 CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). Lancet 2015;385:1843-52. 
  • Punt CJA, Koopman M, Vermeulen L. Advances in precision systemic treatment of colorectal cancer. Nat Rev Clin Oncol. 2017; 4:235-246.
  • Goey K, Elias S, van Tinteren H, Laclé M, Willems S, Offerhaus G, de Leng W, Strengman E, Ten Tije A, Creemers G, van der Velden A, de Jongh F, Erdkamp F, Tanis B, Punt C, Koopman M. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study. Annals of Oncology. 2017; 9:2128-2134.
  • van Rooijen K, Shi Q, Goey K, Meyers J, Heinemann V, Diaz-Rubio E, Aranda E, Falcone A, Green E, de Gramont A, Sargent D, Punt C, Koopman M. Prognostic value of primary tumour resection in synchronous metastatic colorectal cancer: Individual patient data analysis of first-line randomised trials from the ARCAD database. European journal of cancer. 2018; 91: 99-106.
  • Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, Kaplan R, Quirke P, Seymour MT, Richman SD, Meijer GA, Ylstra B, Heideman DAM, de Haan AFJ, Punt CJA, Koopman M. Mismatch repair and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies. Clin Cancer Res 2014;20:5322-5330

  • Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJM, Schrama JG, Erdkamp FLG, Vos AH, van Groeningen CJ, Sinnige HAM, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JHJM, Dalesio O, Punt CJA. Capecitabine, oxaliplatin, bevacizumab with or without cetuximab in advanced colorectal cancer. N Engl J Med 2009;360:563-72
  • Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FLG, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJL, van Bochove A, Sinnige HAM, Creemers GJM, Tesselaar MET, Slee PHThJ, Werter MJBP, Mol L, Dalesio O, Punt CJA. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer, a Dutch Colorectal Cancer Group (DCCG) phase III study. Lancet 2007;370:135-42
  • Koopman M, Kortman GAM , Mekenkamp L, Ligtenberg M, Hoogerbrugge-van der Linden N, Antonini NF , Punt CJA, van Krieken JHJM. The incidence and prognosis of a deficient mismatch repair system (dMMR) caused by hypermethylation of the MLH1-promoter in advanced colorectal cancer patients treated with chemotherapy, a study of the Dutch Colorectal Cancer Group (DCCG). Br J Cancer 2009;100:266-73
  • Mol L, Koopman M, van Gils CWM, Ottevanger PB, Punt CJA. Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. Acta Oncologica 2013; 52:950-5. 
  • Burbach JPM,  Kurk SA, Coebergh van den Braak RJJ, Dik VK, May AM, Meijer GA, Punt CJA, Vink GR, Los M, Hoogerbrugge N, Huijgens PC, Ijzermans JNM, Kuijpers EJ, de Noo ME, Pennings JP, van der Velden AMT, Verhoef C, Siersema PD, van Oijen MGH, Verkooijen HM, Koopman M. Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research. Acta Oncologica. 2016;11:1273-1280.

Publicatielijst op PubMed

  

Verworven onderzoekssubsidies

  1. Effectiveness of adjuvant chemotherapy in preventing recurrence in stage II colon cancer patients with circulating tumor DNA: a cohort based RCT. (2017 MLDS, €250.000)
  2. Organoid cultures and organoid-initiated metastasis models to study metastatic human colon cancer with microsatellite instability. (2017 KWF/Alpe, Unique High Risk Project, € 153.753,90). Project number: ro66o.
  3. Circulating tumor DNA in metastatic colorectal cancer – ORCA project. (2016 Merck/TKI/AvL/UMCU,  € 510.000).
  4. Quality of life during treatment with TAS102 in metastatic colorectal cancer patient – QUALITAS. (2016 Servier, €177.601,38).
  5. Translational research CAIRO3 study (2016 DCCG, €75.000)
  6. Molecular early detection of colorectal cancer – MEDOCC. Stand Up To Cancer (SU2C)-KWF Kankerbestrijding (KWF) Joint Scientific Advisory Committee (2014, in total €6.000.000 of which €476.000 Koopman; SU2C-AACR-DT1415)
  7. Cost-effectiveness analysis of the CAIRO3 study (2014 DCCG, € 45.000)
  8. Improving clinical management of colon cancer through CONNECTION, a nation-wide Colon Cancer Registry and Stratification effort. (2014 AD6/KWF, consortium in total: €3.600.000 of which 500.000 for registry and biobanking)
  9. Translational research in metastatic colorectal cancer (CAIRO3 study; 2014 DCCG, €200.000)
  10. Observational cohort study in colorectal cancer (PICNIC study; 2013-2014 Bayer, Merck, Roche in total: €325.000)
  11. The role of surgery of the primary tumor with few or absent symptoms in patients with synchronous unresectable metastases of colon cancer, a randomized phase III study. CAIRO4 DCCG study (2011 DCCG/Roche, €800.000; CKTO:2012-5697: €519.820)
  12. Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with capecitabine, oxaliplatin, and bevacizumab as first-line treatment in patients with advanced colorectal carcinoma, the phase III CAIRO3 study (2007 DCCG/Roche/Sanofi Aventis, €2.330.000/500.000; CKTO: 2006-17: 222.176)
  13. Aspects of the quality of treatment of the CAIRO study (Sanofi Aventis and Integraal Kanker Centrum Oost (IKO), €160.000)